Raed Alroughani

8.2k total citations
166 papers, 2.2k citations indexed

About

Raed Alroughani is a scholar working on Pathology and Forensic Medicine, Neurology and Oncology. According to data from OpenAlex, Raed Alroughani has authored 166 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pathology and Forensic Medicine, 42 papers in Neurology and 32 papers in Oncology. Recurrent topics in Raed Alroughani's work include Multiple Sclerosis Research Studies (109 papers), Peripheral Neuropathies and Disorders (27 papers) and Polyomavirus and related diseases (27 papers). Raed Alroughani is often cited by papers focused on Multiple Sclerosis Research Studies (109 papers), Peripheral Neuropathies and Disorders (27 papers) and Polyomavirus and related diseases (27 papers). Raed Alroughani collaborates with scholars based in Kuwait, Egypt and United Arab Emirates. Raed Alroughani's co-authors include Samar Farouk Ahmed, Jasem Al–Hashel, Raed Behbehani, Alexey Boyко, Jasem Al-Hashel, Saeed Akhtar, Rabeah Al‐Temaimi, Peter J. Goadsby, A Thussu and Jihad Inshasi and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Neurology.

In The Last Decade

Raed Alroughani

154 papers receiving 2.1k citations

Peers

Countries citing papers authored by Raed Alroughani

Since Specialization

Citations

This map shows the geographic impact of Raed Alroughani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raed Alroughani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raed Alroughani more than expected).

Fields of papers citing papers by Raed Alroughani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raed Alroughani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raed Alroughani. The network helps show where Raed Alroughani may publish in the future.

Co-authorship network of co-authors of Raed Alroughani

This figure shows the co-authorship network connecting the top 25 collaborators of Raed Alroughani. A scholar is included among the top collaborators of Raed Alroughani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raed Alroughani. Raed Alroughani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Role of Dietary and Lifestyle Factors in Multiple Sclerosis Risk in a Middle Eastern Country: A Case-Control Study 2025 ·Neuroepidemiology ·(unknown), Saeed Akhtar, Raed Alroughani	0
2	Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies 2024 ·Therapeutic Advances in Neurological Disorders ·Helmut Butzkueven, Tomáš Kalinčík, Francesco Patti, Mark Slee, Bianca Weinstock‐Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horáková, Eva Havrdová, Anneke van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, (unknown), Tim Spelman, (unknown)	2
3	Safety and effectiveness of disease-modifying therapies after switching from natalizumab 2024 ·Multiple Sclerosis Journal ·Maya Zeineddine, Raed Alroughani, Samar Farouk Ahmed, Samia J. Khoury, (unknown), (unknown), (unknown), Abdullah Al‐Asmi, (unknown), Jihad Inshasi, Riadh Gouider, Saloua Mrabet, Nevin Shalaby, (unknown), (unknown), (unknown), Pascale Salameh, Hani Dimassi, Farid Boumédiène, Bassem Yamout	2
4	Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry 2024 ·Journal of Neurology Neurosurgery & Psychiatry ·Alessio Signori, Marta Ponzano, Tomáš Kalinčík, Serkan Özakbaş, Dana Horáková, Eva Havrdová, Raed Alroughani, Francesco Patti, Jens Kühle, Guillermo Izquierdo, Sara Eichau, Bassem Yamout, Samia J. Khoury, Rana Karabudak, Pierre Grammond, Pierre Duquette, Izanne Roos, Helmut Butzkueven, Anneke van der Walt, Maria Pia Sormani	2
5	Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study 2023 ·Neurology and Therapy ·Jihad Inshasi, (unknown), (unknown), Ali Hassan, Miklós Szólics, (unknown), (unknown), Derk Krieger, (unknown), Taoufik Alsaadi, Béatrice Benedetti, (unknown), Anu Jacob, (unknown), (unknown), Raed Alroughani	5
6	Time Requirements of Healthcare Professionals for Managing Disease-Modifying Therapies for Multiple Sclerosis in Qatar, Kuwait and Bahrain 2023 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), (unknown), Fatema Abdulla, (unknown), Raed Alroughani	1
7	Dietary Factors Associated with Multiple Sclerosis Risk in Kuwait 2022 ·International journal of Nutrition Pharmacology Neurological Diseases ·Rabeah Al‐Temaimi, Raed Alroughani	1
8	External validation of a clinical prediction model in multiple sclerosis 2022 ·Multiple Sclerosis Journal ·(unknown), Sifat Sharmin, Charles B. Malpas, Vahid Shaygannejad, Murat Terzi, Cavit Boz, Bassem Yamout, Samia J. Khoury, Recai Türkoğlu, Rana Karabudak, Nevin Shalaby, Aysun Soysal, Ayşe Altıntaş, Jihad Inshasi, Talal Al‐Harbi, Raed Alroughani, Tomáš Kalinčík	1
9	Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review 2022 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Raed Alroughani, Jihad Inshasi, (unknown), Samar Farouk Ahmed, Yaser Al Malik, (unknown), (unknown), Salman Aljarallah, Edward Cupler, (unknown), (unknown), (unknown), (unknown), (unknown)	3
10	Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA) 2021 ·Clinical Neurology and Neurosurgery ·Raed Alroughani, (unknown), Ahmed Ali Hassan, (unknown), (unknown), (unknown), Naji Riachi, Nabil Akkawi, Salam Koussa, Jihad Inshasi, Taoufik Alsaadi, Samar Farouk Ahmed, (unknown), Magd Zakaria, (unknown)	3
11	The MSBase pregnancy, neonatal outcomes, and women’s health registry 2021 ·Therapeutic Advances in Neurological Disorders ·Vilija Jokubaitis, Olga Skibina, Raed Alroughani, Ayşe Altıntaş, Helmut Butzkueven, Sara Eichau, Yára Dadalti Fragoso, Kerstin Hellwig, (unknown), (unknown), Anneke van der Walt, Orla Gray	5
12	Joinpoint Regression Analysis of Trends in Multiple Sclerosis Incidence in Kuwait: 1980–2019 2020 ·Neuroepidemiology ·Saeed Akhtar, (unknown), Raed Alroughani	13
13	Risk of relapses during pregnancy among multiple sclerosis patients 2019 ·Multiple Sclerosis and Related Disorders ·Raed Alroughani, Saeed Akhtar, Maya Zeineddine, (unknown), (unknown), Samar Farouk Ahmed, Raed Behbehani, Samia J. Khoury, Jasem Al–Hashel, Bassem Yamout	19
14	Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines 2019 ·Multiple Sclerosis and Related Disorders ·Bassem Yamout, Mohammad Ali Sahraian, Saeed Bohlega, Mohammed Aljumah, (unknown), Maurice Dahdaleh, Jihad Inshasi, (unknown), (unknown), Samia J. Khoury, (unknown), Salam Koussa, (unknown), (unknown), Taoufik Alsaadi, (unknown), (unknown), Magd Zakaria, Raed Alroughani	75
15	Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study) 2017 ·Queensland's institutional digital repository (The University of Queensland) ·Celia Oreja‐Guevara, Raed Alroughani, David Brassat, (unknown), Pamela McCombe, Brian Steingo, (unknown), David Margolin, Nadia Daizadeh, (unknown), P. Vermersch	1
16	Age-Period-Cohort Modeling of Multiple Sclerosis Incidence Rates in Kuwait: 1980–2014 2017 ·Neuroepidemiology ·Saeed Akhtar, (unknown), Jasem Al-Hashel, Raed Alroughani	3
17	Alemtuzumab Provides Durable Efficacy Over 6 Years in Patients With Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II) (S24.006) 2017 ·Neurology ·Edward Fox, David Brassat, Raed Alroughani, Simon Broadley, Jeffrey Cohen, Hans‐Peter Hartung, Eva Havrdová, Celia Oreja‐Guevara, Krzysztof Selmaj, B. Singer, Patrick Vermersch, Sibyl Wray, David Margolin, Karthinathan Thangavelu, Madalina Chirieac, Alasdair Coles	2
18	Retrospective Cohort Study of Gender Differential in Risk of Multiple Sclerosis in Kuwait 2016 ·Neuroepidemiology ·Saeed Akhtar, Raed Alroughani, Samar Farouk Ahmed, Jasem Al–Hashel	7
19	Neurological Complications in Sickle Cell Disease 2016 ·(unknown), Raed Alroughani, (unknown), (unknown)	5
20	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study 2016 ·Journal of Neurology Neurosurgery & Psychiatry ·Ilya Kister, Tim Spelman, Raed Alroughani, Jeannette Lechner‐Scott, Pierre Duquette, François Grand’Maison, Mark Slee, Alessandra Lugaresi, Michael Barnett, Pierre Grammond, Gerardo Iuliano, Raymond Hupperts, Eugenio Pucci, María Trojano, Helmut Butzkueven	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact